Indian snakeroot has been used in traditional Ayurvedic medicine in India, mainly for high blood pressure and mental illnesses such as schizophrenia and anxiety. Also, one of the chemicals in Indian snakeroot is the same as a prescription drug called reserpine. Reserpine has been used to treat high blood pressure, schizophrenia, and some symptoms of poor circulation.
How does it work ?
Uses & Effectiveness ?
Insufficient Evidence for
- Anxiety. Early research shows that Indian snakeroot can reduce anxiety in some people when used for about 20 days. It is not known if Indian snakeroot has any benefit when used for longer periods of time.
- High blood pressure. Early research shows that Indian snakeroot reduces high blood pressure.
- Insomnia. Early research shows that taking Indian snakeroot along with two other herbs might help insomnia. It is not known if Indian snakeroot helps with insomnia when used alone.
- Insect bite.
- Liver disease.
- A mental disorder marked by hallucinations and delusion (psychosis).
- Rheumatoid arthritis (RA).
- Seizure disorder (epilepsy).
- Snake bite.
- Stomach pain.
- Other conditions.
Special Precautions and Warnings
Anxiety: Indian snakeroot contains a chemical that might make anxiety worse. But some research shows that Indian snakeroot might improve anxiety. Until more is known, use Indian snakeroot with caution in people with anxiety.
Depression: Indian snakeroot can cause depression, especially in people who have had depression before.
Diabetes: Indian snakeroot can lower blood sugar levels. It might cause sugar levels to go too low if taken with other diabetes medicines.
Shock therapy (electroconvulsive therapy, ECT): Indian snakeroot should not be used by people who are receiving ECT. Stop taking Indian snakeroot at least one week before beginning ECT.
Gallbladder disease: Indian snakeroot might make gallbladder disease worse.
Low blood pressure: Don't use Indian snakeroot if you have low blood pressure. Indian snakeroot can lower blood pressure even further.
A tumor in the adrenal glands which causes dangerously high blood pressure (pheochromocytoma): Avoid Indian snakeroot - it might make dangerously high blood pressure worse.
Stomach ulcers: Avoid Indian snakeroot - it could make stomach ulcers worse.
An autoimmune disease that causes widespread swelling (systemic lupus erythematosus or SLE): Indian snakeroot has caused symptoms like SLE and could make it worse.
Alcohol interacts with INDIAN SNAKEROOT
Alcohol can cause sleepiness and drowsiness. Indian snakeroot might also cause sleepiness and drowsiness. Taking large amounts of Indian snakeroot along with alcohol might cause too much sleepiness.
Digoxin (Lanoxin) interacts with INDIAN SNAKEROOT
Digoxin (Lanoxin) helps the heart beat more strongly. Indian snakeroot seems to slow the heartbeat. Taking Indian snakeroot along with digoxin might decrease the effectiveness of digoxin. Do not take Indian snakeroot if you are taking digoxin (Lanoxin).
Levodopa interacts with INDIAN SNAKEROOT
Levodopa is used for Parkinson's disease. Taking Indian snakeroot along with levodopa might decrease the effectiveness of levodopa. It is not clear why this interaction might occur. To be on the safe side, do not take Indian snakeroot if you are taking levodopa.
Medications for depression (MAOIs) interacts with INDIAN SNAKEROOT
Indian snakeroot contains a chemical that affects the body. This chemical might increase the side effects of some medications used for depression.
Some of these medications used for depression include phenelzine (Nardil), tranylcypromine (Parnate), and others.
Medications for mental conditions (Antipsychotic drugs) interacts with INDIAN SNAKEROOT
Indian snakeroot seems to have a calming effect. Medications for mental conditions also help calm you down. Taking Indian snakeroot along with some medications for mental conditions might increase the risk of side effects of medications for mental conditions.
Some of these medications include chlorpromazine (Thorazine), clozapine (Clozaril), fluphenazine (Prolixin), haloperidol (Haldol), olanzapine (Zyprexa), perphenazine (Trilafon), prochlorperazine (Compazine), quetiapine (Seroquel), risperidone (Risperdal), thioridazine (Mellaril), thiothixene (Navane), and others.
Propranolol (Inderal) interacts with INDIAN SNAKEROOT
Propanolol (Inderal) is used to decrease blood pressure. Indian snakeroot also seems to reduce blood pressure. Taking Indian snakeroot along with propanolol (Inderal) might cause your blood pressure to go too low.
Sedative medications (Barbiturates) interacts with INDIAN SNAKEROOT
Indian snakeroot might cause sleepiness and drowsiness. Medications that cause sleepiness are called sedatives. Taking Indian snakeroot along with sedative medications might cause too much sleepiness.
Stimulant drugs interacts with INDIAN SNAKEROOT
Stimulant drugs speed up the nervous system. By speeding up the nervous system, stimulant medications can make you feel jittery and speed up your heartbeat. Indian snakeroot might also speed up the nervous system. Taking Indian snakeroot along with stimulant drugs might cause serious problems including increased heart rate and high blood pressure. Avoid taking stimulant drugs along with Indian snakeroot.
Some stimulant drugs include diethylpropion (Tenuate), epinephrine, phentermine (Ionamin), pseudoephedrine (Sudafed), and many others.
Do not take this combination
Ephedrine interacts with INDIAN SNAKEROOT
Ephedrine can speed up the nervous system and make you feel jittery. Indian snakeroot can calm you down and make you sleepy. Taking Indian snakeroot along with ephedrine can decrease the effects of ephedrine.
Medications used for depression (Tricyclic antidepressants) interacts with INDIAN SNAKEROOT
Taking some medications used for depression might decrease the effects of Indian snakeroot.
Some of these medicines used for depression include amitriptyline (Elavil), imipramine (Tofranil), and others.
Water pills (Diuretic drugs) interacts with INDIAN SNAKEROOT
Indian snakeroot might affect the heart. "Water pills" can decrease potassium in the body. Low potassium levels can also affect the heart and increase the risk of side effects from Indian snakeroot.
Some "water pills" that can deplete potassium include chlorothiazide (Diuril), chlorthalidone (Thalitone), furosemide (Lasix), hydrochlorothiazide (HCTZ, HydroDuril, Microzide), and others.
Be cautious with this combination
Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416. View abstract.
Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev. 2016;10:CD011286. View abstract.
Gentile S., Persico M., Orlando C., Le Grazie C., Di Padova C., Coltorti M. Effect of different doses of S-adenosyl-L-methionine (SAMe) on nicotinic acid-induced hyperbilirubinaemia in Gilbert's syndrome. Scand J Clin Lab Invest 1988;48(6):525-529. View abstract.
Glorioso S, Todesco S, Mazzi A, et al. Double-blind, multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985;5:39-49. View abstract.
Goren JL, Stoll AL, Damico KE, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004;24:1501-7. View abstract.
Green T., Steingart L., Frisch A., Zarchi O., Weizman A., Gothelf D. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. J Neural Transm 2012;119(11):1417-1423. View abstract.
Ideo G. [S-Adenosylmethionine: plasma levels in hepatic cirrhosis and preliminary results of its clinical use in hepatology. Double-blind study]. Minerva Med 1975;66(33):1571-1580. View abstract.
Adeniyi, A. A., Brindley, G. S., Pryor, J. P., and Ralph, D. J. Yohimbine in the treatment of orgasmic dysfunction. Asian J Androl 2007;9(3):403-407. View abstract.
Albus, M., Zahn, T. P., and Breier, A. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur.Arch.Psychiatry Clin.Neurosci. 1992;241(6):337-344. View abstract.
Bagheri, H., Schmitt, L., Berlan, M., and Montastruc, J. L. Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants. Br J Clin Pharmacol 1992;34(6):555-558. View abstract.
Berlin, I., Crespo-Laumonnier, B., Cournot, A., Landault, C., Aubin, F., Legrand, J. C., and Puech, A. J. The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol.Ther. 1991;49(4):362-369. View abstract.
Boon, N. A., Elliott, J. M., Grahame-Smith, D. G., John-Green, T., and Stump, K. A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]- dihydroergocryptine. J Auton.Pharmacol 1983;3(2):89-95. View abstract.
Braddock, L., Cowen, P. J., Elliott, J. M., Fraser, S., and Stump, K. Binding of yohimbine and imipramine to platelets in depressive illness. Psychol.Med 1986;16(4):765-773. View abstract.
Charney, D. S., Heninger, G. R., and Sternberg, D. E. Assessment of alpha 2 adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci 6-7-1982;30(23):2033-2041. View abstract.
Giampreti, A., Lonati, D., Locatelli, C., Rocchi, L., and Campailla, M. T. Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol.(Phila) 2009;47(8):827-829. View abstract.
Landis, E. and Shore, E. Yohimbine-induced bronchospasm. Chest 1989;96(6):1424. View abstract.
Mann, K., Klingler, T., Noe, S., Roschke, J., Muller, S., and Benkert, O. Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Arch.Sex Behav. 1996;25(1):1-16. View abstract.
Mustonen, P., Savola, J., and Lassila, R. Atipamezole, an imidazoline-type alpha(2)-adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine. Thromb.Res 8-1-2000;99(3):231-237. View abstract.
Myers, A. and Barrueto, F., Jr. Refractory priapism associated with ingestion of yohimbe extract. J Med Toxicol. 2009;5(4):223-225. View abstract.
Riley AJ, Goodman R, Kellett JM, and et al. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual Marital Ther 1989;4(1):17-26.
Rowland, D. L., Kallan, K., and Slob, A. K. Yohimbine, erectile capacity, and sexual response in men. Arch Sex Behav 1997;26(1):49-62. View abstract.
Siddiqui, M. A., More-O'Ferrall, D., Hammod, R. S., Baime, R. V., and Staddon, A. P. Agranulocytosis associated with yohimbine use. Arch.Intern.Med 6-10-1996;156(11):1235-1237. View abstract.
Susset, J. G., Tessier, C. D., Wincze, J., Bansal, S., Malhotra, C., and Schwacha, M. G. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989;141(6):1360-1363. View abstract.
Swann, A. C. Mechanisms of impulsivity in bipolar disorder and related illness. Epidemiol.Psichiatr.Soc. 2010;19(2):120-130. View abstract.
Swann, A. C., Birnbaum, D., Jagar, A. A., Dougherty, D. M., and Moeller, F. G. Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol.Psychiatry 5-15-2005;57(10):1209-1211. View abstract.
Achor RW, Hanson NO, Gifford RW Jr. Hypertension treated with Rauwolfia serpentina (whole root) and with reserpine; controlled study disclosing occasional severe depression. J Am Med Assoc. 1955 Oct 29;159(9):841-5. View abstract.
Azmi MB, Qureshi SA. Methanolic Root Extract of Rauwolfia serpentina Benth Improves the Glycemic, Antiatherogenic, and Cardioprotective Indices in Alloxan-Induced Diabetic Mice. Adv Pharmacol Sci. 2012;2012:376429. View abstract.
Azmi MB, Qureshi SA. Rauwolfia serpentina improves altered glucose and lipid homeostasis in fructose-induced type 2 diabetic mice. Pak J Pharm Sci. 2016 Sep;29(5):1619-1624. View abstract.
Briggs GB, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
Dey A, Pandey DK. HPTLC detection of altitudinal variation of the potential antivenin stigmasterol in different populations of the tropical ethnic antidote Rauvolfia serpentina. Asian Pac J Trop Med. 2014 Sep;7S1:S540-5. View abstract.
Eurlings MC, Lens F, Pakusza C, Peelen T, Wieringa JJ, Gravendeel B. Forensic identification of Indian snakeroot (Rauvolfia serpentina Benth. ex Kurz) using DNA barcoding. J Forensic Sci. 2013 May;58(3):822-30. View abstract.
Ezeigbo II, Ezeja MI, Madubuike KG, Ifenkwe DC, Ukweni IA, Udeh NE, Akomas SC. Antidiarrhoeal activity of leaf methanolic extract of Rauwolfia serpentina. Asian Pac J Trop Biomed. 2012 Jun;2(6):430-2. doi: 10.1016/S2221-1691(12)60070-7. View abstract.
Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992;53:207-9. View abstract.
Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-22. View abstract.
Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann Pharmacother 2010;44:1022-9. View abstract.
Kumar S, Singh A, Bajpai V, Srivastava M, Singh BP, Ojha S, Kumar B. Simultaneous Determination of Bioactive Monoterpene Indole Alkaloids in Ethanolic Extract of Seven Rauvolfia Species using UHPLC with Hybrid Triple Quadrupole Linear Ion Trap Mass Spectrometry. Phytochem Anal. 2016 Sep;27(5):296-303. View abstract.
Lobay D. Rauwolfia in the Treatment of Hypertension. Integr Med (Encinitas). 2015 Jun;14(3):40-6. View abstract.
Lowinger P. Rauwolfia serpentina in the control of anxiety. Psychiatr Q. 1957 Jul;31(3):445-53. View abstract.
Milman N, Scheibel J, Jessen O. Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study. Acta Derm Venereol 1980;60:85-7. View abstract.
Pathania S, Randhawa V, Bagler G. Prospecting for novel plant-derived molecules of Rauvolfia serpentina as inhibitors of Aldose Reductase, a potent drug target for diabetes and its complications. PLoS One. 2013 Apr 17;8(4):e61327. View abstract.
Rani PU, Naidu MU. Subjective and polysomnographic evaluation of a herbal preparation in insomnia. Phytomedicine 1998;5:253-7.
Ruck B, Shih RD, Marcus SM. Hypertensive crisis from herbal treatment of impotence. Am J Emerg Med. 1999;17:317-318.
Ryan JJ, Hanes DA, Corroon J, Taylor J, Bradley R. Prospective safety evaluation of a cardiovascular health dietary supplement in adults with prehypertension and stage I hypertension. J Altern Complement Med 2019;25(2):249-56. doi:10.1089/acm.2018.0311. View abstract.
Sagi S, Avula B, Wang YH, Khan IA. Quantification and characterization of alkaloids from roots of Rauwolfia serpentina using ultra-high performance liquid chromatography-photo diode array-mass spectrometry. Anal Bioanal Chem. 2016 Jan;408(1):177-90. View abstract.
Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urol 1993;41:343-5. View abstract.
Sheldon MB, Kotte JH. Effect of Rauwolfia serpentina and reserpine on the blood pressure in essential hypertension; a long-term double-blind study. Circulation. 1957 Aug;16(2):200-6. View abstract.
Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998;159:122-4. View abstract.
Vakil RJ. A clinical trial of Rauwolfia serpentina in essential hypertension. Br Heart J. 1949 Oct;11(4):350-5. View abstract.
VandenBrink, B. M., Foti, R. S., Rock, D. A., Wienkers, L. C., and Wahlstrom, J. L. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos. 2012;40(1):47-53. View abstract.
Wilkins RW, Judson WE. The use of Rauwolfia serpentina in hypertensive patients. N Engl J Med. 1953 Jan 8;248(2):48-53. View abstract.
Wylie KR. Yohimbine and sinusitis. Br J Psychiatry. 1996;169(3):384-5. View abstract.
Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.